Indeed, efficacy of epidermal growth factor receptor (EGFR) inhibitors such as gefitinib and erlotinib is markedly reduced in non-small-cell lung cancers exhibiting the EGFR-T790M mutation.104 Amplification and mutations in anaplastic lymphoma kinase have been identified in pediatric neuroblastoma, but secondary mutations in the anaplastic lymphoma kinase tyrosine kinase domain or anaplastic lymphoma kinase fusion gene amplifications are observed after crizotinib treatment leading to the disease relapse.104. This evidence concerns the gene EGFR and neuroblastoma.